CLOVIS ONCOLOGY INC (CLVS)
US1894641000 - Common Stock
We assign a fundamental rating of 1 out of 10 to CLVS. CLVS was compared to 588 industry peers in the Biotechnology industry. CLVS may be in some trouble as it scores bad on both profitability and health. CLVS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CLVS has reported negative net income.
In the past year CLVS has reported a negative cash flow from operations.
CLVS had negative earnings in each of the past 5 years.
CLVS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The profitability ratios for CLVS are negative, so there is not much use analyzing them.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CLVS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CLVS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CLVS has been increased compared to 1 year ago.
Compared to 1 year ago, CLVS has a worse debt to assets ratio.
2.2 Solvency
CLVS has an Altman-Z score of -16.18. This is a bad value and indicates that CLVS is not financially healthy and even has some risk of bankruptcy.
CLVS has a Altman-Z score of -16.18. This is amonst the worse of the industry: CLVS underperforms 87.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.18 |
ROIC/WACCN/A
WACC2.06%
2.3 Liquidity
CLVS has a Current Ratio of 0.14. This is a bad value and indicates that CLVS is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.14, CLVS is not doing good in the industry: 96.24% of the companies in the same industry are doing better.
A Quick Ratio of 0.12 indicates that CLVS may have some problems paying its short term obligations.
CLVS's Quick ratio of 0.12 is on the low side compared to the rest of the industry. CLVS is outperformed by 96.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.14 | ||
| Quick Ratio | 0.12 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 36.04% over the past year.
The Revenue for CLVS has decreased by -14.78% in the past year. This is quite bad
Measured over the past years, CLVS shows a very strong growth in Revenue. The Revenue has been growing by 331.02% on average per year.
EPS 1Y (TTM)36.04%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q30.36%
Revenue 1Y (TTM)-14.78%
Revenue growth 3Y15.96%
Revenue growth 5Y331.02%
Revenue growth Q2Q-19.13%
3.2 Future
CLVS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.36% yearly.
Based on estimates for the next years, CLVS will show a small growth in Revenue. The Revenue will grow by 4.17% on average per year.
EPS Next Y28.29%
EPS Next 2Y28.47%
EPS Next 3Y21.43%
EPS Next 5Y9.36%
Revenue Next Year-14%
Revenue Next 2Y1.79%
Revenue Next 3Y3.93%
Revenue Next 5Y4.17%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CLVS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLVS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CLVS's earnings are expected to grow with 21.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.47%
EPS Next 3Y21.43%
5. Dividend
5.1 Amount
No dividends for CLVS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CLOVIS ONCOLOGY INC
NASDAQ:CLVS (12/20/2022, 8:19:57 PM)
After market: 0.078 0 (-3.94%)0.0812
0 (-5.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap11.77M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.38
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.14 | ||
| Quick Ratio | 0.12 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)36.04%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y28.29%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-14.78%
Revenue growth 3Y15.96%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y